Inhibikase Therapeutics (IKT) EBT Margin Growth (3y) (2023)

Inhibikase Therapeutics (IKT) EBT Margin Growth (3y) (2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 132.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -674,462.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 8,006.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 71,157.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -5,319.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,980.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 31,363.00
10 Inhibikase Therapeutics 420.72 Mn 261.70 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -44.04 Bn
Sep 30, 2023 -425,423.00
Jun 30, 2023 -517,080.00
Mar 31, 2023 -718,247.00